StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/304% below fair value
$29.94−0.54 (-1.76%)

Close on Nov 13, 2026Market cap $1.54BP/E –Yield 0.00%

Immunocore ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$42.25M. The highest annual figure on record is -$42.25M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$42.25M–
FY2024Dec 31, 2024-$66.26M–
FY2023Dec 31, 2023-$55.55M–
FY2022Dec 31, 2022-$46.41M–
FY2021Dec 31, 2021-$166.99M–

More Immunocore figures

See a number that looks wrong?